MediciNova, Inc. (MNOV) - Financial and Strategic SWOT Analysis
Review
Reference Code: GDPH61527FSA Publication Date: SEP 2012
4350 La Jolla Village Drive, Suite 950 Phone +1 858 3731500 Revenue NA
San Diego, CA Fax +1 858 3737000 Net Profit -17.73 (million USD)
92122 Website www.medicinova.com Employees 14
Pharmaceuticals &
United States Exchange MNOV [NASDAQ] Industry
Healthcare
Company Overview
MediciNova, Inc. (MediciNova) is a bio pharmaceutical company with focus on the acquiring and developing and commercializing
novel, small-molecule therapeutics for the treatment of diseases with unmet medical need in the US. MediciNova built a portfolio
of product candidates by acquiring product rights through license agreements with mid-sized Japanese pharmaceutical
companies.
Key Executives SWOT Analysis
Name Title MediciNova, Inc., SWOT Analysis
Yuichi Iwaki, M.D., Ph.D. Chief Executive Officer Strengths Weaknesses
Jeff Himawan Chairman
Partnership and Collaborations History of Operating Losses
Arlene M. Morris Director
Focused Research and Lack of In-House Manufacturing
Hiroaki Shigeta Director
Development Facilities
Tatsuo Izumi Director
Source: Annual Report, Company Website, Primary and Secondary
Research, GlobalData Opportunities Threats
Share Data Strong Product Pipeline Highly Competitive
MediciNova, Inc. Environment
Emerging Markets
Share Price (USD) as on 10-Sep- 1.90 Uncertain R&D Outcomes
2012
EPS (USD) -1.20
Source: Annual Report, Company Website, Primary and Secondary Research,
Market Cap (million USD) 31 GlobalData
Enterprise Value (million USD) 23
Shares Outstanding (million) 16
Source: Annual Report, Company Website, Primary and Secondary
Research, GlobalData
Financial Performance Recent Developments
Aug 09, 2012 MediciNova Reports Revenue Of $0.5m In Q2
2012
May 10, 2012 MediciNova Reports Q1 2012 Results
Mar 29, 2012 MediciNova Reports 2011 Results
Nov 30, 2011 MediciNova Appoints Kousuke Nakata To
Board
Source: Annual Report, Company Website, Primary and Secondary Research,
GlobalData
Source: Annual Report, Company Website, Primary and Secondary
Research, GlobalData
MediciNova, Inc. (MNOV) - Financial and Strategic SWOT Analysis Reference Code: GDPH61527FSA
Review
Source : www.globalcompanyintelligence.com Page 1
© GlobalData. This report is a licensed product and is not to be copied, reproduced, shared or resold in any form
Table of Contents
Table of Contents ............................................................................................................................................................................... 2
List of Tables .................................................................................................................................................................................. 4
List of Figures ................................................................................................................................................................................. 4
Section 1 - About the Company.......................................................................................................................................................... 5
MediciNova, Inc. - Key Facts .............................................................................................................................................................. 5
MediciNova, Inc. - Key Employees ..................................................................................................................................................... 6
MediciNova, Inc. - Key Employee Biographies ................................................................................................................................... 7
MediciNova, Inc. - Major Products and Services ................................................................................................................................ 8
MediciNova, Inc. - Pharmaceutical Pipeline Products Data ................................................................................................................ 9
MediciNova, Inc., Pipeline Products by Therapy Area .................................................................................................................... 9
MediciNova, Inc., Pipeline Products by Development Phase........................................................................................................ 10
MediciNova, Inc. - History................................................................................................................................................................. 12
MediciNova, Inc. - Company Statement ........................................................................................................................................... 14
MediciNova, Inc. - Locations And Subsidiaries................................................................................................................................. 16
Head Office ................................................................................................................................................................................... 16
Other Locations & Subsidiaries ..................................................................................................................................................... 16
Section 2 – Company Analysis ......................................................................................................................................................... 17
MediciNova, Inc. - Business Description .......................................................................................................................................... 17
MediciNova, Inc. - SWOT Analysis ................................................................................................................................................... 18
SWOT Analysis - Overview........................................................................................................................................................... 18
MediciNova, Inc. - Strengths ......................................................................................................................................................... 18
Strength - Partnership and Collaborations ................................................................................................................................ 18
Strength - Focused Research and Development ...................................................................................................................... 18
Strength - Strong Intellectual Property Portfolio ........................................................................................................................ 18
MediciNova, Inc. - Weaknesses .................................................................................................................................................... 18
Weakness - History of Operating Losses .................................................................................................................................. 18
Weakness - Lack of In-House Manufacturing Facilities ............................................................................................................. 19
MediciNova, Inc. - Opportunities ................................................................................................................................................... 19
Opportunity - Strong Product Pipeline ....................................................................................................................................... 19
Opportunity - Emerging Markets ............................................................................................................................................... 19
Opportunity - Changing Demographics ..................................................................................................................................... 19
MediciNova, Inc. - Threats ............................................................................................................................................................ 19
Threat - Highly Competitive Environment .................................................................................................................................. 19
Threat - Uncertain R&D Outcomes ........................................................................................................................................... 20
Threat - Tightening of FDA’s Regulatory Oversight ................................................................................................................... 20
MediciNova, Inc. - Key Competitors ................................................................................................................................................. 21
Section 3 – Company Financial Ratios ............................................................................................................................................. 22
Financial Ratios - Capital Market Ratios........................................................................................................................................... 22
Financial Ratios - Annual Ratios ...................................................................................................................................................... 22
Performance Chart ........................................................................................................................................................................... 23
Financial Performance...................................................................................................................................................................... 23
Financial Ratios - Interim Ratios....................................................................................................................................................... 24
Financial Ratios - Ratio Charts ......................................................................................................................................................... 25
Section 4 – Company’s Lifesciences Financial Deals and Alliances ................................................................................................ 26
MediciNova, Inc., Pharmaceuticals & Healthcare, Deals By Year, 2006 to YTD 2012 ................................................................. 26
MediciNova, Inc. (MNOV) - Financial and Strategic SWOT Analysis Reference Code: GDPH61527FSA
Review
Source : www.globalcompanyintelligence.com Page 2
© GlobalData. This report is a licensed product and is not to be copied, reproduced, shared or resold in any form
MediciNova, Inc., Pharmaceuticals & Healthcare, Deals By Type, 2006 to YTD 2012 ................................................................. 27
MediciNova, Inc., Recent Deals Summary ....................................................................................................................................... 28
Section 5 – Company’s Recent Developments ................................................................................................................................ 29
MediciNova, Inc., Recent Developments ...................................................................................................................................... 29
Aug 09, 2012: MediciNova Reports Revenue Of $0.5m In Q2 2012 ......................................................................................... 29
May 10, 2012: MediciNova Reports Q1 2012 Results .................